Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Osteosarcoma (OS) is the most common primary bone malignancy.
• The genetic underpinnings of OS pathogenesis and chemoresistance remain poorly understood.
• Chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) is implicated in malignant tumor progression.

Purpose of the Study:

• To investigate the role of CHD1L in osteosarcoma tumorigenesis and chemoresistance.
• To explore CHD1L's impact on cisplatin (cDDP) sensitivity in OS cells.
• To elucidate the molecular mechanisms by which CHD1L influences OS drug resistance.

Main Methods:

• Analysis of CHD1L expression in OS patient samples, particularly in relation to cisplatin resistance.
• In vitro studies involving CHD1L knockdown in OS cells to assess proliferation, apoptosis, and chemoresistance.
• Evaluation of cancer stem cell properties and multidrug resistance protein 1 (MDR-1) expression.
• Investigation of signaling pathways including ERK1/2, AKT, and NF-κB.
• In vivo xenograft models to validate the effects of CHD1L suppression on chemoresistance.

Main Results:

• CHD1L expression is significantly upregulated in OS, especially in cisplatin-resistant cases.
• CHD1L knockdown increases OS cell sensitivity to cisplatin, lowering IC50 values.
• Suppression of CHD1L reduces proliferation, induces apoptosis, and diminishes cancer stem cell characteristics in resistant OS cells.
• CHD1L knockdown decreases MDR-1 expression and inhibits ERK1/2, AKT, and NF-κB signaling pathways.
• In vivo experiments confirm that CHD1L suppression mitigates cisplatin resistance in OS xenografts.

Conclusions:

• CHD1L plays a crucial role in modulating chemoresistance in osteosarcoma.
• Targeting CHD1L presents a potential strategy for overcoming cisplatin resistance in OS.
• Further research into CHD1L's mechanisms could lead to novel therapeutic approaches for OS patients.